XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexorLijia Pan, Zhixiang Wu|Journal of Experimental & Clinical Cancer Research|2021Cited by 29
Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastomaKai Chen, Zhixiang Wu|Oncotarget|2016Cited by 16
P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in NeuroblastomaCheng Cheng, Zhixiang Wu|Molecular & Cellular Proteomics|2023Cited by 15